Literature DB >> 10706865

Rifampicin-dependent antibodies bind a similar or identical epitope to glycoprotein IX-specific quinine-dependent antibodies.

J K Burgess1, J A Lopez, L E Gaudry, B H Chong.   

Abstract

The drug-dependent antibody of a patient with rifampicin-induced thrombocytopenia was characterized using the antigen-capture enzyme-linked immunosorbent assay (MAIPA assay), flow cytometry, and immunoprecipitation. The antibody was found to bind glycoprotein (GP) Ib-IX but not GPIIb-IIIa because (1) it immunoprecipitated drug-dependently the former but not the latter glycoprotein complex and (2) the MAIPA assay showed strong rifampicin-dependent antibody binding when anti-GPIb-IX monoclonal antibodies (mAbs) (AK2 and FMC25) but not anti-GPIIb-IIIa mAbs (AP2, SZ21, and SZ22) were used to capture the antigen. The antibody binding site was further localized to the GPIX subunit of the GPIb-IX complex because flow cytometric analysis revealed drug-dependent antibody binding to L cells transfected with human GPIbbeta and GPIX complementary DNA (L betaIX cells) but not with human GPIbalpha and GPIbbeta complementary DNA (L alphabeta cells). Finally, in the MAIPA assay, the rifampicin-dependent antibody almost completely cross-blocked the binding of the anti-GPIX mAb (SZ1) to platelets. Similar cross-blocking of SZ1binding to platelets by the quinine-dependent antibodies was also observed. This finding not only confirms that the epitope of the rifampicin-dependent antibody is on GPIX but it is also identical to or located in close proximity to that of the quinine-dependent antibody and SZ1. Further characterization of the epitopes of these antibodies may have important implications for a general understanding of the mechanism of drug-induced thrombocytopenia. (Blood. 2000;95:1988-1992)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10706865

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  A hypothesis that explains the heterogeneity of drug-induced immune thrombocytopenia.

Authors:  Renhao Li
Journal:  Blood       Date:  2010-01-28       Impact factor: 22.113

2.  A 39-year-old female patient with metastatic rectal cancer develops thrombocytopenia.

Authors:  Haifaa Dbouk; Simon Mentha; Deborah Mukherji; Jean Lee; Ali Haydar; Ali Shamseddine; Eileen M O'Reilly; Leonard Saltz; Ghassan K Abou-Alfa
Journal:  Gastrointest Cancer Res       Date:  2014-03

Review 3.  Drug-induced immune thrombocytopenia.

Authors:  Patricia M L A van den Bemt; Ronald H B Meyboom; Antoine C G Egberts
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

4.  Acute subdural hemorrhage associated with rifampicin-induced thrombocytopenia.

Authors:  Sa-Yoon Kang; Jay Chol Choi; Ji-Hoon Kang; Jung Seok Lee
Journal:  Neurol Sci       Date:  2009-12-04       Impact factor: 3.307

Review 5.  Drug-induced thrombocytopenia.

Authors:  Gian Paolo Visentin; Chao Yan Liu
Journal:  Hematol Oncol Clin North Am       Date:  2007-08       Impact factor: 3.722

6.  Thrombocytopenic purpura as a presenting manifestation of tubercular lymphadenitis.

Authors:  Sameer Bakhshi; Madhulika Kabra; Venkaleswaran K Iyer; L S Arya
Journal:  Indian J Pediatr       Date:  2003-12       Impact factor: 1.967

Review 7.  A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia.

Authors:  D M Arnold; S Kukaswadia; I Nazi; A Esmail; L Dewar; J W Smith; T E Warkentin; J G Kelton
Journal:  J Thromb Haemost       Date:  2013-01       Impact factor: 5.824

Review 8.  Hypersensitivity reaction with multi-organ failure following re-exposure to rifampicin: case report and review of the literature including WHO spontaneous safety reports.

Authors:  Lisa Brockhaus; Yasmin Schmid; Anna C Rast; Alexandra E Rätz Bravo; Kathrin Scherer Hofmeier; Anne B Leuppi-Taegtmeyer
Journal:  BMC Pharmacol Toxicol       Date:  2019-02-12       Impact factor: 2.483

9.  Acute drug-induced immune thrombocytopenia - A work of articaine.

Authors:  Ingvild Jenssen Laegreid; Mats Irgen Olsen; Jon Inge Harr; Renathe Henriksen Grønli; Trude Victoria Mørtberg; Siw Leiknes Ernstsen; Maria Therese Ahlen
Journal:  Transfusion       Date:  2022-03-19       Impact factor: 3.337

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.